• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

    6/18/25 6:43:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email

    Jury concludes J&J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer

    A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products.

    The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer.

    During the trial, the Dean Omar Branham Shirley legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson & Johnson had internal knowledge of asbestos in its talc supply dating back decades yet continued to market the products as safe for daily use.

    J&J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi, a lifelong user of the company's Baby Powder on herself and her children, was diagnosed with mesothelioma in 2021.

    "Johnson & Johnson knew its talc Baby Powder could kill, and they chose to keep selling it anyway, despite the availability of safer cornstarch-based powders," said Ben Braly, one of Ms. Paluzzi's attorneys. "We are grateful to the jury for holding them to account."

    Ms. Paluzzi, 84, raised seven children in single-bathroom homes for 20 years. Today, she has 10 grandchildren and is suffering through her illness.

    The legal team included Ben Braly, Anthony Bianco and Aaron Chapman of Dean Omar Branham Shirley, along with Brian Kenney of Early, Lucarelli, Sweeney & Mesienkothen, LLC and Amy Carter with the Carter Law Group.

    "Johnson & Johnson sold their product as safe and took advantage of the trust of families like Ms. Paluzzi's," said Dean Omar Branham Shirley partner Trey Branham. "She used it every day on herself and her children. The jury saw that betrayal and delivered justice."

    The case is Janice Paluzzi v. Johnson & Johnson, Civil Action No. 21-2109, filed in Suffolk County Superior Court in Massachusetts.

    About Dean Omar Branham Shirley

    Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of irresponsible conduct of others. For more information, please visit http://www.dobslegal.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250618099844/en/

    Media Contact:

    Mark Annick

    800-559-4534

    [email protected]

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    SEC Filings

    See more
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/10/25 5:06:51 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Johnson & Johnson

      SD - JOHNSON & JOHNSON (0000200406) (Filer)

      5/28/25 4:05:16 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care